Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Chemotherapy and Ivarmacitinib in Resectable Esophageal Squamous Cell Carcinoma
NCT07505186Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, ivarmacitinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Aug 2026; status: recruiting.
02
Drugs
camrelizumabivarmacitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07505186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505186.